5-fluoro-2-(methylthio)benzo[d]oxazole | 439608-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 5-fluoro-2-(methylthio)benzo[d]oxazole
• 英文别名: 5-fluoro-2-methylsulfanyl-benzooxazole；5-fluoro-2-methylsulfanyl-1,3-benzoxazole
• CAS: 439608-25-0
• 化学式: C₈H₆FNOS
• mdl: MFCD25963475
• 分子量: 183.206
• InChiKey: LDVWZOXQGBLZCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  51.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-fluoro-2-(methylthio)benzo[d]oxazole 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 4-(5-fluorobenzooxazol-2-yl)-1,4-diazabicyclo[3.2.2]nonane hydrochloride
  参考文献：
  名称：

  Pharmaceutical compositions for CNS and other disorders

  摘要：

  公开号：

  EP1219622B1
• 作为产物：
  描述：

  2-氨基-4-氟苯酚 在 potassium carbonate 作用下， 生成 5-fluoro-2-(methylthio)benzo[d]oxazole
  参考文献：
  名称：

  Pharmaceutical compositions for CNS and other disorders

  摘要：

  公开号：

  EP1219622B1

文献信息

• HMOX1 inducers
  申请人：Mitobridge Inc.

  公开号：US10766888B1

  公开（公告）日：2020-09-08

  The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.

  本发明涉及结构（I）的化合物作为血红素氧合酶1（HMOX 1）诱导剂。本发明还涉及一种控制哺乳动物体内血红素氧合酶1的活性或数量，或活性和数量的方法。这里提供了变量的定义。
• Pharmaceutical composition for the treatment of CNS and other disorders
  申请人：——

  公开号：US20020086871A1

  公开（公告）日：2002-07-04

  The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.

  本发明涉及一种治疗哺乳动物中枢神经系统（CNS）和其他疾病的方法，包括人类，在哺乳动物中给予一种穿透中枢神经系统的α7烟碱受体激动剂。同时涉及含有药用可接受载体和穿透中枢神经系统的α7烟碱受体激动剂的药物组合物。
• Convenient synthesis of 2-alkynylbenzazoles through Sonogashira cross-coupling reaction between thioethers and terminal alkynes
  作者：Anca Paun、Mihaela Matache、Florina Enache、Ioana Nicolau、Codruta C. Paraschivescu、Petre Ionita、Irina Zarafu、Vasile I. Parvulescu、Gérald Guillaumet

  DOI：10.1016/j.tetlet.2015.08.001

  日期：2015.9

  We describe herein the synthesis of 2-alkynylbenzoxazole and 2-alkynylbenzothiazole derivatives through the Sonogashira cross-coupling reaction of the corresponding thioethers and terminal alkynes under aerobic conditions, using CuI and Pd(dppf)Cl2 as catalysts. The synthetic methodology allows the convenient cross-coupling of heteroaromatic substrates with a wide variety of aromatic and aliphatic

  我们在本文中描述了通过在CuI和Pd（dppf）Cl 2作为催化剂的条件下，相应的硫醚和末端炔烃的Sonogashira交叉偶联反应，合成2-炔基苯并恶唑和2-炔基苯并噻唑衍生物。合成方法可实现杂芳族底物与多种芳族和脂族炔烃的便捷交叉偶联，产率中等至良好。在脱硫的Sonogashira交叉偶联反应中，也研究了巯基苯并恶唑和苯并噻唑的行为。值得注意的是，尽管二炔副产物的量增加，但该反应在有氧条件下比在惰性气氛下进行得更好。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS AND OTHER DISORDERS
  申请人：O'Neill Thomas Brian

  公开号：US20070099904A1

  公开（公告）日：2007-05-03

  The present invention relates to compounds of formula I The substituent designations are as disclosed. At least one of B Q, D and E is nitrogen. The present invention also provides a method of treating disorders of the Central Nervous System such as schizophrenia and cognitive dysfunction.

  本发明涉及I式化合物。取代基的标识如所披露的那样。B、Q、D和E中至少有一个是氮。本发明还提供了一种治疗中枢神经系统疾病，如精神分裂症和认知功能障碍的方法。
• Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
  作者：Christopher J. O’Donnell、Bruce N. Rogers、Brian S. Bronk、Dianne K. Bryce、Jotham W. Coe、Karen K. Cook、Allen J. Duplantier、Edelweiss Evrard、Mihaly Hajós、William E. Hoffmann、Raymond S. Hurst、Noha Maklad、Robert J. Mather、Stafford McLean、Frank M. Nedza、Brian T. O’Neill、Langu Peng、Weimin Qian、Melinda M. Rottas、Steven B. Sands、Anne W. Schmidt、Alka V. Shrikhande、Douglas K. Spracklin、Diane F. Wong、Andy Zhang、Lei Zhang

  DOI：10.1021/jm9015075

  日期：2010.2.11

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.